#United States #Los Angeles #securities lawsuit #DJS Law Group #Skye Bioscience

Skye Bioscience Sued for Securities Violations

On December 4, 2025, the DJS Law Group announced a class action lawsuit against Skye Bioscience, Inc. (NASDAQ: SKYE), highlighting significant allegations concerning violations of securities laws. The lawsuit focuses on claims that Skye made inaccurate and misleading statements about its operations, particularly regarding the efficacy of its drug candidate, nimacimab.

Overview of the Case

According to the complaint filed, the class period spans from November 4, 2024, to October 3, 2025. During this time, it is alleged that the Company's public statements regarding nimacimab did not accurately reflect its performance, leading shareholders to suffer financial losses. Investors who purchased shares during this timeframe are being urged to come forward and participate in potential legal actions.

Timeline and Next Steps

The deadline for affected shareholders to join the class action is set for January 16, 2026. To participate, investors need to register as shareholders and will subsequently receive updates regarding the status of the lawsuit through monitoring software implemented by the DJS Law Group. Importantly, there are no costs associated with joining the lawsuit, making it accessible for all investors.

Allegations Against Skye

The core allegations suggest that Skye Bioscience failed to disclose critical information about the drug's ineffectiveness, which constituted misleading practices under the Securities Exchange Act of 1934. Specifically, Sections 10(b) and 20(a) along with SEC Rule 10b-5 are cited, outlining the legal framework under which investors are seeking redress. The claims assert that this failure significantly impacted stock prices, leading to unjust losses for shareholders.

Legal Advocacy from DJS Law Group

The DJS Law Group is positioned as a key advocate for investors in this instance, focusing on improving returns through litigation. The firm is known for handling securities class actions and has represented numerous high-profile clients in past legal fights. Their expertise aims to ensure that the interests of investors are well-protected against corporate misconduct.

Why It Matters

For shareholders, especially those invested in Skye, this lawsuit is a crucial opportunity to reclaim losses. As public trust in corporate governance continues to be tested, the outcome of such legal battles can have significant implications for market integrity and investor confidence.

How to Get Involved

If you are among the shareholders of Skye Bioscience who purchased stocks during the class period, it’s advisable to reach out to the DJS Law Group. The firm offers a straightforward process for participation, including enrolling you in ongoing updates and monitoring the progress of the case. By doing so, you position yourself to recover losses effectively.

In conclusion, the class action lawsuit against Skye Bioscience serves as a reminder of the importance of transparency and reliability in corporate communications. As the legal proceedings unfold, stakeholders will be watching closely to see how these allegations are addressed and the protective measures that will be implemented for investors moving forward.